SINTX Technologies, Inc. (NASDAQ:SINT) is an advanced ceramics company that has evolved from its initial focus on the research and development of silicon nitride for use in human interbody implants to becoming a diversified player in various fields, including biomedical, technical, and antipathogenic applications.
Business Overview
SINTX's core strength lies in the manufacturing, research, and development of advanced ceramics for external partners. The company currently operates manufacturing facilities in Salt Lake City, Utah, and Millersville, Maryland, both of which are FDA and ANVISA registered, ISO 13485:2016 certified, and ASD9100D certified.
SINTX's diversification strategy has enabled the company to focus on its core competencies and explore new revenue-generating opportunities across three key business industries - antipathogenic, technical (including armor), and biomedical. This approach has allowed SINTX to connect with current and new customers, partners, and manufacturers, with the goal of leveraging its expertise in high-tech ceramics to create innovative products and solutions.
Biomedical Applications
SINTX's initial focus was the development and commercialization of products made from silicon nitride for use in spinal fusion and hip and knee replacement applications. The company believes it is the first and only manufacturer to use silicon nitride in medical applications, primarily focused on spine fusion therapies. SINTX's silicon nitride products have been shown to be biocompatible, bioactive, antipathogenic, and to have superb bone affinity, making them suitable for long-term human implantation.
Technical Applications
SINTX's silicon nitride is believed to have the best combination of mechanical, thermal, and electrical properties of any technical ceramic material. It is a high-performance technical ceramic with high strength, toughness, and hardness, and is extremely resistant to thermal shock and impact. SINTX has obtained AS9100D certification and ITAR registration to facilitate entry into the aerospace and protective armor markets.
Antipathogenic Applications
The discovery in 2020 that SINTX's silicon nitride inactivates SARS-CoV-2, the virus that causes COVID-19, has opened new markets and applications for the company's material. SINTX believes that by incorporating its unique composition of silicon nitride antipathogenic powder into products such as face masks, filters, and wound care devices, it is possible to manufacture surfaces that inactivate pathogens, thereby limiting the spread of infection and disease.
Financials
For the fiscal year ended December 31, 2023, SINTX reported annual revenue of $2.6 million, a decrease from the previous year's revenue of $3.1 million. The company's annual net loss for the year was $8.3 million, compared to a net loss of $7.4 million in the prior year. SINTX's annual operating cash flow was -$14.1 million, and its annual free cash flow was -$14.6 million.
In the first quarter of 2024, SINTX reported total revenue of $687,000, a 27% increase compared to the same period in 2023. Product revenue increased by 29% to $309,000, while grant and contract revenue increased by 26% to $378,000. The company's gross profit for the quarter was $464,000, up 10% from the first quarter of 2023.
SINTX's research and development expenses decreased by 8% to $2.0 million in the first quarter of 2024, while general and administrative expenses decreased by 4% to $1.1 million. Sales and marketing expenses decreased by 21% to $246,000. The company's net loss for the quarter was $886,000, compared to a net loss of $293,000 in the same period of the prior year.
Liquidity
As of March 31, 2024, SINTX had cash and cash equivalents of $5.8 million, compared to $3.3 million as of December 31, 2023. The company's current ratio was 1.84, and its quick ratio was 1.67, indicating a strong liquidity position.
SINTX has been able to successfully raise capital when needed, with its most recent public offerings in February and March 2024 raising a combined $2.8 million in gross proceeds. The company also has an active at-the-market (ATM) equity distribution agreement with Maxim Group LLC, which has provided additional funding. As of March 31, 2024, SINTX had approximately $70,000 remaining available for sale under the ATM program.
However, the company continues to generate operating losses and use cash in operations. SINTX's continuation as a going concern is dependent upon its ability to increase sales and/or raise additional funds through the capital markets. The company is actively pursuing various strategies to drive revenue growth, including expanding the use of silicon nitride in areas outside of spinal fusion applications and exploring the potential of its silicon nitride powder in personal protection products.
Risks and Challenges
SINTX faces several risks and challenges, including:
- Continued operating losses and cash burn
- Dependence on a limited number of customers for a significant portion of revenue
- Intense competition in the medical device, technical ceramics, and antipathogenic markets
- Regulatory hurdles and approvals required for new product introductions
- Potential intellectual property disputes
- Ability to successfully execute its diversification and growth strategies
Outlook and Conclusion
SINTX's diversification strategy has opened up new avenues for growth beyond its initial focus on spinal implants. The company's expertise in advanced ceramics, particularly silicon nitride, positions it well to capitalize on opportunities in the biomedical, technical, and antipathogenic sectors.
While SINTX continues to face financial and operational challenges, the company's recent public offerings and active ATM program provide it with the necessary capital to fund its ongoing operations and strategic initiatives. The successful commercialization of its silicon nitride-based products in new markets could be a significant driver of future growth and profitability.
Overall, SINTX's transition from a spinal implant-focused company to a diversified advanced ceramics player presents both opportunities and risks. Investors should closely monitor the company's progress in executing its diversification strategy and its ability to generate sustainable revenue and cash flow growth.